-- ACTengine(R) patient recruitment remains on track; as of end of July, a 
      total of 27 patients have been treated with IMA201, IMA202 or IMA203 
      across different cancer indications 
 
   -- TCR Bispecifics pipeline advancing with progress towards clinical trial 
      initiation of IMA401 and preclinical proof-of-concept for second TCER(R) 
      molecule IMA402 
 
   -- Cash and cash equivalents as well as Other financial assets of $229.1 
      million1 (EUR192.8 million) as of June 30, 2021, funding company 
      operations into 2023

Tuebingen, Germany and Houston, TX, August 10, 2021 -- Immatics https://www.globenewswire.com/Tracker?data=xDYL5iT8OJ2HBhMTSMX-D6V-5zaOfJSnFTHbd7030cZVqxp-0aPor_hUHYw5qloKKi_qVKgEJSjBYUMmhBzirA== N.V. https://www.globenewswire.com/Tracker?data=fc06okP-LbsCu76YBBErbL3lCe7LqFfA-Ti3HuYiTw7IXjB2fj5a4w_AfJNpiJ8eBCwFXo9OkFoRkDKxhUR8pw== (NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended June 30, 2021 and provided a business update on its progress over the reporting period.

"An important development during the second quarter of 2021 was a significant increase in patient enrollment for our ACTengine(R) programs, " said Harpreet Singh, Ph.D., CEO of Immatics. "Following the positive initial results we provided in the first quarter, we now look forward to announcing more advanced data including safety, biological activity and the assessment of anti-tumor activity for a range of different cancer indications in the second half of 2021."

"In addition to the upcoming clinical data for our ACTengine(R) trials, we are excited to move our second therapeutic modality towards the clinic," added Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics. "We are encouraged by the entirety of the IMA401 data set, which following discussions with regulatory authorities puts us in a strong position to submit our IMA401 Clinical Trial Application during the fourth quarter of 2021. Our TCER(R) pipeline is further strengthened by our second TCR Bispecifics program, IMA402, for which we recently presented preclinical proof-of-concept data."

Second Quarter 2021 and Subsequent Company Progress

https://www.globenewswire.com/Tracker?data=M2hbH8hERUvzjy_G7AmPxJEM6Na1kJ_DnhFq9FPEq2oQ_NSKqjfPz_SwctVm7i3iDgJ92_RtUyjy2Ky5VvaB1VlTFnNLaDhCwkEKgi5CTKHbTroQWQJgvrTh3YPLUEDBYC7eMpQukNvHDsWa_clPTA== Adoptive Cell Therapy Programs 


   -- ACTengine(R) IMA200 series -- Patient recruitment remains on track and 
      the additional trial sites initiated in Europe and the US have supported 
      the acceleration of recruitment. As of end of July, 27 patients have been 
      treated in the IMA200 series. The first-in-human basket trials for 
      IMA201, IMA202 and IMA203 include patients with recurrent and/or 
      refractory solid cancers utilizing TCR-engineered T cells (TCR-T) 
      directed against the cancer targets MAGEA4/A8, MAGEA1 and PRAME, 
      respectively. 
 
   -- In March 2021 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-data-update-dose-escalation-ongoing-actenginer 
      , Immatics reported initial safety and biological data as well as data 
      showing first clinical anti-tumor activity for 10 patients enrolled in 
      these trials. Patients were treated at initial dose levels below one 
      billion transduced cells, which was presumed to be sub-therapeutic as per 
      data published from across the industry. 
 
   -- The next data update, which will cover safety, biological activity, and 
      the assessment of anti-tumor activity across different cancer indications, 
      including patients treated at higher dose levels (dose levels 2 and 3), 
      will be provided by the company within the second half of 2021.

https://www.globenewswire.com/Tracker?data=bI9dHvbBw07AsGhkRJrOt548MJjoXXuQOVX63fUUpVdtgmO9VvBlvvRQMCZm2ISPX7XR9sN0J25nfw4rQ2OSbQwKOb1NAzNMBVLRDwZPlf8= TCR https://www.globenewswire.com/Tracker?data=oNMCQhn0IBBUs97lAcW9sEbqf06-BJ0VBIhxEYMgxQx5naaLCbyKZW8e1ubrBx45iRKgBI6FJmklNIAPOjv6dKZdJyn7SjNCewCHbkjt01c= Bispecifics https://www.globenewswire.com/Tracker?data=iJ8wy-vIjqIT8nv27gNZMTsj15FJqrQiL0efjsFou1gaSEkgugntHP-4LzzFYANZuwsDS58OQ82O4Exjlv8VDPpsxPwYyp4v6ygm50JCPEw= Progra https://www.globenewswire.com/Tracker?data=LaK6JmRjP7IjP72wPpYUIAEGFk98EbPGngdu5kAaL7W-d6LVi_CIsBQb-hjI7iztXAA55PfLC6L6I3POPHQzRQ== ms 


   -- IMA401 -- Immatics has discussed the proposed clinical trial design for 
      its first TCER(R) program IMA401, as well as the preclinical data package 
      covering safety and efficacy data in a scientific advisory meeting2 with 
      the Paul-Ehrlich Institute, the German regulatory authority. The company 
      also completed the first Good Manufacturing Practices (GMP) production 
      batch delivering a high production yield. IMA401 remains on track for 
      submission of a CTA in the fourth quarter of 2021 and patient recruitment 
      will be initiated in the first half 2022. 
 
   -- IMA402 -- The company presented 
      https://investors.immatics.com/news-releases/news-release-details/immatics-presents-preclinical-proof-concept-data-tcr-0 
      preclinical proof-of-concept data on IMA402 at the 17th Annual PEGS 
      Boston Protein Engineering and Cell Therapy Summit in May. IMA402 is 
      directed against a peptide derived from the cancer target PRAME, a 
      protein that is frequently expressed in many solid cancers, thereby 
      supporting the program's potential to address a broad range of cancer 
      patients and indications. Data demonstrated tumor cell killing in vitro 
      and complete regressions of established tumors in an in vivo tumor model. 
      Immatics has selected a lead candidate for the clinical program and 
      initiated manufacturing activities.

https://www.globenewswire.com/Tracker?data=XltVcbItrw48tl3RqexORRLV-gkep8ECCnHu3mcfIdBjuw6r7Vq8DRxGlPxKaI5XWjY0sLLcqspb2pkLAqmRIVjcwwet5oH3IDQ2t-2WApcyNpZ9eTWi2mxiKR6jg5GL Corporate Development 


   -- As of July 1, 2021, Immatics adopted a one-tier structure for its Board 
      of Directors. As part of this process, the company's CEO Harpreet Singh, 
      Ph.D., has joined the Board. 
 
   -- Friedrich von Bohlen und Halbach, Ph.D., was appointed as successor of 
      Christof Hettich, L.L.D. Dr. von Bohlen und Halbach is Managing Partner 
      and co-founder of dievini Hopp BioTech Holding, managing the investments 
      of Dietmar Hopp and family.

Second Quarter 2021 Financial Results

Cash Position: Cash and cash equivalents as well as Other financial assets total EUR192.8 million ($229.1 million(1) ) as of June 30, 2021, compared to EUR216.7 million ($257.5 million(1) ) as of March 31, 2021.

Revenue: Total revenue, consisting of revenue from collaboration agreements, was EUR5.2 million ($6.2 million(1) ) for the three months ended June 30, 2021, compared to EUR6.9 million ($8.2 million(1) ) for the three months ended June 30, 2020.

Research and Development Expenses: R&D expenses were EUR20.3 million ($24.1 million(1) ) for the three months ended June 30, 2021, compared to EUR16.5 million ($19.7 million(1) ) for the three months ended June 30, 2020. The increase is mainly due to expanded clinical activities for the ACTengine(R) IMA200 series, as well as GMP manufacturing for the TCER(R) compound, IMA401.

General and Administrative Expenses: G&A expenses were EUR8.3 million ($9.9 million(1) ) for the three months ended June 30, 2021, compared to EUR10.1 million ($12.0 million(1) ) for the three months ended June 30, 2020. The decrease is mainly due to one-time expenses in connection with the listing of the Company in 2020.

Net Loss: Net loss was EUR23.8 million ($28.3 million(1) ) for the three months ended June 30, 2021, compared to EUR21.3 million ($25.3 million(1) ) for the three months ended June 30, 2020.

Upcoming Investor Conferences 


   -- BTIG Virtual Biotechnology Conference -- August 9-10, 2021 
 
   -- Goldman Sachs London Biotech Symposium -- September 7, 2021 
 
   -- Jefferies London Healthcare Conference -- November 16-18, 2021

To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.

Full financial statements can be found in the current report on Form 6-K filed with the Securities and Exchange Commission (SEC) and published on the SEC website under www.sec.gov.

(1) All amounts translated using the exchange rate published by the European Central Bank in effect as of June 30, 2021 (1 EUR = 1.1884 USD).

(2) in Europe, equivalent to a pre-IND meeting at FDA.

About ACTengine(R) IMA200 series

Each of the product candidates of the IMA200 series is based on Immatics' proprietary ACTengine(R) approach in which the patient's own T cells are genetically engineered to express a novel, proprietary TCR directed against a defined cancer target. The modified T cells are then reinfused into the patient to attack the tumor, an approach also known as TCR-T. ACTengine(R) programs IMA201, IMA202 and IMA203 are currently in clinical development for the treatment of solid tumor indications, both in the US and in Germany. All ACTengine(R) product candidates can be rapidly manufactured utilizing a proprietary manufacturing process designed to enhance T cell engraftment and persistence in vivo.

The ACTengine(R) T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT).

About TCER(R)

(MORE TO FOLLOW) Dow Jones Newswires

August 10, 2021 07:00 ET (11:00 GMT)